| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2113048 | Cancer Letters | 2013 | 7 Pages |
Attenuated Salmonella is an approved oral life vaccine that is currently entering pre-clinical cancer vaccination studies as a promising DNA carrier. In a syngeneic mouse model for neuroblastoma, oral gavage of Salmonella typhimurium (SL7207) carrying recent generated survivin DNA vaccines induced a stronger cellular anti-NB immune response than gene gun application or injection of lentivirally transduced bone marrow-derived DCs. The level of Salmonella-associated side effects was not significant as indicated by unaffected survivin-mediated hematopoiesis and wound healing. We believe that our findings provide an important baseline to translate Salmonella-based DNA vaccination into a clinical application for neuroblastoma.
► SL7207 were dismantled as most effective vaccine carrier for survivin-based DNA vaccination in a syngeneic neuroblastoma. ► As a second-best DNA delivery system emerged the application of lentiviral-transduced DCs. ► Gene gun application appeared the least effective procedure for DNA vaccination. ► DC vaccination was more effective in inducing a cellular immune response when loaded with peptide epitopes. ► The level of Salmonella-associated side effects was not significant.
